Overview

Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial

Status:
Not yet recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

The objective of this prospective, single-center randomized controlled trial is to identify the optimal adjuvant intravesical therapy in patients with intermediate risk (IR) non muscle invasive bladder cancer by comparing two commonly utilized intravesical regimens; intravesical immunotherapy (BCG) and intravesical chemotherapy.

Phase:

N/A

Details

Lead Sponsor:

Mansoura University

Treatments:

Epirubicin